Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Self-Treatment Results In Lower Overall Health Care Costs For COPD Sufferers
Individuals suffering from chronic obstructive pulmonary disorder (COPD) can experience significant savings in healthcare costs by employing a self-treatment program with the judicious use of medications, according to the results of a new study. The self-treatment program achieves these savings by reducing the duration of flare-ups.
generic viagra online
Medicare Part D Healthy For Enrollees
Medicare beneficiaries" activities of daily living (ADL) improved in their first year of the Medicare Part D senior prescription drug plan, according to a ground-breaking study presented at the Annual AcademyHealth meetings in Chicago today.
News of the day
Free Clinics Affected By Primary Care Physician Shortage
In the face of growing numbers of uninsured and low-income patients due to the economy, some free clinics are having difficulty meeting the increased demand, the Cleveland Plain Dealer reports. Since March, the Parma Health Ministry, in Cleveland, "which has only two volunteer primary care physicians who see patients in the evenings, has had to turn people away." Nicole Lamoureux, executive director of the National Association of Free Clinics, said the number of people seeking care at free clinics had increased by 40 to 50 percent in recent months, and that many of the newcomers have recently lost insurance coverage.
Diagnostics

Trinity Biotech Announces TRI-statTM CLIA Submission To FDA

Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced it has submitted its CLIA application for its TRI-stat™ point-of-care HbA1c product to the FDA. TRI-stat™ is designed to measure HbA1c, also known as glycated hemoglobin, a measure of a patient"s average blood sugar control over the last two to three months. The availability of TRI-stat™ will improve overall efficiency of diabetes care by delivering HbA1c values during the patient"s visit to the doctor"s office. Utilizing a patented boronate affinity and two-phase optical system, together with a simple, fully automated, plug-and-play instrument design, TRI-stat™ offers highly accurate results in minutes while eliminating the need for refrigeration found with the other three competing products. Diabetes is the fourth leading cause of death by disease in the world. According to the International Diabetes Federation, the number of people diagnosed with type 2 diabetes worldwide has increased from 30 million to more than 246 million over the last two decades. This figure is projected to increase further to 380 million by 2025. In the U.S., some 20.8 million Americans (7 percent of the population) have the disease with a further 54 million Americans considered to be pre-diabetic. The test will allow Trinity to address a doctors" office global market of approximately $200 million. Commenting on the news, Ronan O"Caoimh, CEO, said, "Following the successful completion of our CLIA trials in four independent sites in the USA, I am delighted to announce the submission of our TRI-stat™ CLIA application to the FDA. The test will allow us to address a market which continues to grow significantly each year due to the need for decentralisation of testing to doctors" offices, the recommendations from the American Diabetes Association and the International Diabetes Federation for more frequent patient monitoring and the ongoing increase in the prevalence of diabetes. We will be showcasing the product at the AACC Clinical Lab Expo in Chicago on 21-23 July, 2009." Trinity Biotech


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009